VASOACTIVE COCKTAILS FOR ERECTILE DYSFUNCTION: CHEMICAL STABILITY OF PGE1, PARAVERINE AND PHENTOLAMINE
- 1 August 1998
- journal article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 160 (2) , 551-555
Abstract
Vasoactive cocktails are widely used in diagnosing and treating erectile dysfunction, especially in poor responders to prostaglandin E1 (PGE1). However, very little information as to their chemical interactions and stability is available, despite the huge amount of published work regarding their clinical efficacy. Obviously, medical and legal problems are involved. We analyzed four kinds of vasoactive cocktails, composed of papaverine, phentolamine and PGE1 in different combinations, using High Performance Liquid Chromatography analysis after 5 to 60 days of storage at temperatures between 2 and 8C. SPSS MANOVA analysis and a t-test for paired samples were used for statistical purposes. Papaverine and phentolamine concentrations showed no significant variations during the 2 month study, ranging from a minimum of 96.75 +/− 1.20 to a maximum of 103.00 +/− 0.20% of the starting values. In the same period, PGE1 showed an accelerated degradation profile, reaching concentration values, after 60 days, of 76.00 +/− 2.28% and 70.20 +/− 2.02% when added to phentolamine or papaverine respectively and 70.00 +/− 2.40% with both. Papaverine and phentolamine are characterized by chemical stability when blended together or with PGE1. Papaverine and/or phentolamine increase the naturally occurring degradation of PGE1 in physiological solution. This effect is most evident in the first 10 days. Papaverine has the greatest deteriorating effect on PGE1. A safe and proper use of these cocktails should take into account the variations of PGE1 concentration.Keywords
This publication has 10 references indexed in Scilit:
- Forskolin: A Promising New Adjunct to Intracavernous PharmacotherapyJournal of Urology, 1996
- Stability study of prostaglandin E1(PGE1) in physiological solutions by liquid chromatography (HPLC)International Journal of Pharmaceutics, 1995
- Followup Results of a Combination of Calcitonin Gene-Related Peptide and Prostaglandin E1 in the Treatment of Erectile DysfunctionJournal of Urology, 1993
- Prostaglandin E1 and the Nitric Oxide Donor Linsidomine for Erectile Failure: A Diagnostic Comparative Study of 40 PatientsJournal of Urology, 1993
- Four-Drug Intracavernous Therapy for Impotence Due to Corporeal Veno-Occlusive DysfunctionJournal of Urology, 1993
- Intracavernous Self-Injection of Vasoactive Drugs in the Treatment of Impotence: 8-Year Experience with 615 CasesJournal of Urology, 1991
- Penile Response to Intracavernosal Vasoactive Intestinal Polypeptide Alone and in Combination with Other Vasoactive AgentsBritish Journal of Urology, 1989
- The pH Analysis of Papaverine-Phentolamine and Prostaglandin E 1 for Pharmacologic ErectionJournal of Urology, 1989
- Prostaglandin E1 Versus Phentolamine/Papaverine for the Treatment of Erectile Impotence: A Double-Blind ComparisonJournal of Urology, 1989
- Erectile Responses to Intracavernous Papaverine and Phentolamine: Comparison of Single and Combined DeliveryJournal of Urology, 1988